Literature DB >> 15890907

Receptor binding, fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble G glycoprotein of Hendra virus.

Katharine N Bossart1, Gary Crameri, Antony S Dimitrov, Bruce A Mungall, Yan-Ru Feng, Jared R Patch, Anil Choudhary, Lin-Fa Wang, Bryan T Eaton, Christopher C Broder.   

Abstract

Hendra virus (HeV) and Nipah virus (NiV) are closely related emerging viruses comprising the Henipavirus genus of the Paramyxovirinae, which are distinguished by their ability to cause fatal disease in both animal and human hosts. These viruses infect cells by a pH-independent membrane fusion event mediated by their attachment (G) and fusion (F) glycoproteins. Previously, we reported on HeV- and NiV-mediated fusion activities and detailed their host-cell tropism characteristics. These studies also suggested that a common cell surface receptor, which could be destroyed by protease, was utilized by both viruses. To further characterize the G glycoprotein and its unknown receptor, soluble forms of HeV G (sG) were constructed by replacing its cytoplasmic tail and transmembrane domains with an immunoglobulin kappa leader sequence coupled to either an S-peptide tag (sG(S-tag)) or myc-epitope tag (sG(myc-tag)) to facilitate purification and detection. Expression of sG was verified in cell lysates and culture supernatants by specific affinity precipitation. Analysis of sG by size exclusion chromatography and sucrose gradient centrifugation demonstrated tetrameric, dimeric, and monomeric species, with the majority of the sG released as a disulfide-linked dimer. Immunofluorescence staining revealed that sG specifically bound to HeV and NiV infection-permissive cells but not to a nonpermissive HeLa cell line clone, suggesting that it binds to virus receptor on host cells. Preincubation of host cells with sG resulted in dose-dependent inhibition of both HeV and NiV cell fusion as well as infection by live virus. Taken together, these data indicate that sG retains important native structural features, and we further demonstrate that administration of sG to rabbits can elicit a potent cross-reactive neutralizing antibody response against infectious HeV and NiV. This HeV sG glycoprotein will be exceedingly useful for structural studies, receptor identification strategies, and vaccine development goals for these important emerging viral agents.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15890907      PMCID: PMC1112112          DOI: 10.1128/JVI.79.11.6690-6702.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  Nipah virus outbreak(s) in Bangladesh, January-April 2004.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2004-04-23

Review 2.  Viral glycoprotein-mediated cell fusion assays using vaccinia virus vectors.

Authors:  Katharine N Bossart; Christopher C Broder
Journal:  Methods Mol Biol       Date:  2004

Review 3.  Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know.

Authors:  Giuseppe Pantaleo; Richard A Koup
Journal:  Nat Med       Date:  2004-08       Impact factor: 53.440

4.  Emerging infectious diseases. Nipah virus (or a cousin) strikes again.

Authors:  Martin Enserink
Journal:  Science       Date:  2004-02-20       Impact factor: 47.728

5.  Folding and oligomerization properties of a soluble and secreted form of the paramyxovirus hemagglutinin-neuraminidase glycoprotein.

Authors:  G D Parks; R A Lamb
Journal:  Virology       Date:  1990-10       Impact factor: 3.616

6.  Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase.

Authors:  T R Fuerst; E G Niles; F W Studier; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

Review 7.  Structure, function, and intracellular processing of paramyxovirus membrane proteins.

Authors:  T G Morrison
Journal:  Virus Res       Date:  1988-05       Impact factor: 3.303

8.  Reducing agent-sensitive dimerization of the hemagglutinin-neuraminidase glycoprotein of Newcastle disease virus correlates with the presence of cysteine at residue 123.

Authors:  J P Sheehan; R M Iorio; R J Syddall; R L Glickman; M A Bratt
Journal:  Virology       Date:  1987-12       Impact factor: 3.616

9.  Conversion of a class II integral membrane protein into a soluble and efficiently secreted protein: multiple intracellular and extracellular oligomeric and conformational forms.

Authors:  R G Paterson; R A Lamb
Journal:  J Cell Biol       Date:  1990-04       Impact factor: 10.539

10.  Fatal fruit bat virus sparks epidemics in southern Asia.

Authors:  Declan Butler
Journal:  Nature       Date:  2004-05-06       Impact factor: 49.962

View more
  85 in total

Review 1.  Modes of paramyxovirus fusion: a Henipavirus perspective.

Authors:  Benhur Lee; Zeynep Akyol Ataman
Journal:  Trends Microbiol       Date:  2011-04-20       Impact factor: 17.079

2.  Surface density of the Hendra G protein modulates Hendra F protein-promoted membrane fusion: role for Hendra G protein trafficking and degradation.

Authors:  Shannon D Whitman; Rebecca Ellis Dutch
Journal:  Virology       Date:  2007-02-27       Impact factor: 3.616

3.  Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies.

Authors:  Zhongyu Zhu; Antony S Dimitrov; Katharine N Bossart; Gary Crameri; Kimberly A Bishop; Vidita Choudhry; Bruce A Mungall; Yan-Ru Feng; Anil Choudhary; Mei-Yun Zhang; Yang Feng; Lin-Fa Wang; Xiaodong Xiao; Bryan T Eaton; Christopher C Broder; Dimiter S Dimitrov
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

4.  Differential rates of protein folding and cellular trafficking for the Hendra virus F and G proteins: implications for F-G complex formation.

Authors:  Shannon D Whitman; Everett Clinton Smith; Rebecca Ellis Dutch
Journal:  J Virol       Date:  2009-06-24       Impact factor: 5.103

5.  A recombinant Hendra virus G glycoprotein subunit vaccine protects nonhuman primates against Hendra virus challenge.

Authors:  Chad E Mire; Joan B Geisbert; Krystle N Agans; Yan-Ru Feng; Karla A Fenton; Katharine N Bossart; Lianying Yan; Yee-Peng Chan; Christopher C Broder; Thomas W Geisbert
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

Review 6.  Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses.

Authors:  Ponraj Prabakaran; Zhongyu Zhu; Xiaodong Xiao; Arya Biragyn; Antony S Dimitrov; Christopher C Broder; Dimiter S Dimitrov
Journal:  Expert Opin Biol Ther       Date:  2009-03       Impact factor: 4.388

7.  Development of an acute and highly pathogenic nonhuman primate model of Nipah virus infection.

Authors:  Thomas W Geisbert; Kathleen M Daddario-DiCaprio; Andrew C Hickey; Mark A Smith; Yee-Peng Chan; Lin-Fa Wang; Joseph J Mattapallil; Joan B Geisbert; Katharine N Bossart; Christopher C Broder
Journal:  PLoS One       Date:  2010-05-18       Impact factor: 3.240

8.  Ephrin-B2 expression critically influences Nipah virus infection independent of its cytoplasmic tail.

Authors:  Lena Thiel; Sandra Diederich; Stephanie Erbar; Dennis Pfaff; Hellmut G Augustin; Andrea Maisner
Journal:  Virol J       Date:  2008-12-24       Impact factor: 4.099

9.  Targeted strategies for henipavirus therapeutics.

Authors:  Katharine N Bossart; John Bingham; Deborah Middleton
Journal:  Open Virol J       Date:  2007-09-28

10.  Antiviral activity of gliotoxin, gentian violet and brilliant green against Nipah and Hendra virus in vitro.

Authors:  Mohamad Aljofan; Michael L Sganga; Michael K Lo; Christina L Rootes; Matteo Porotto; Adam G Meyer; Simon Saubern; Anne Moscona; Bruce A Mungall
Journal:  Virol J       Date:  2009-11-04       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.